Skip to main content

Table 1 Model assumptions on pneumococcal disease and vaccination effects

From: Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia

Parameter Value Source
Population distribution   
Birth cohort 550,000 [25, 26]
20-39 years age group 8,770,937 [25, 26]
40-64 years group 5,536,238 [25, 26]
≥ 65 years group 1,051,371 [25, 26]
Life expectancy at birth (years) 74.2 [30]
PCV7 vaccine coverage 495,000 90% of birth cohort [12]
PCV7 vaccine compliance 100%  
Pneumococcal disease incidence   
S. pneumonia isolated 100%  
Unspecified meningitis and bacteraemia 36% [24]
All cause pneumonia 30% [23]
Paediatric fatality rate   
Meningitis 0.2 [31]
Bacteraemia 0.1 [31]
All cause pneumonia 0% [31]
Otitis media 0% [31]
Adult fatality rate   
Meningitis 9.0% [32]
Bacteraemia 4.6% [32]
All cause pneumonia 0.17% [32]
Otitis media 0% [32]
PCV7 serotype coverage 66.7% [28]
PCV7 efficacy in infants   
Pneumococcal meningitis 97.4% [27]
Pneumococcal bacteraemia 97.4% [27]
All cause pneumonia 6% [27]
Otitis media 7% [27]
PCV7 efficacy decline over time (efficacy waning)   
≤ 5 years post-vaccination 1% p.a. [22]
6-10 years post-vaccination 3% p.a. [22]
Reduction on IPD in adults (herd effects)   
20-39 years group 32% [29]
40-64 years group 8% [29]
≥ 65 years group 18% [29]